Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03994185
Other study ID # IOD-P2-19-01
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2020
Est. completion date December 31, 2020

Study information

Verified date April 2020
Source Merit Medical Systems, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-center, non-randomized phase 2, first-in-iliac artery study, to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of peripheral arterial occlusive disease in symptomatic subjects with de novo or restenotic lesions in the common iliac artery (CIA) and/or external iliac artery (EIA), including lesions at the aortic bifurcation.


Description:

Approximately 30 subjects will be enrolled. Post study procedure subjects will have planned follow-up visits at 4 weeks, 24, 36 and 52 weeks, and unscheduled visits as medically necessary,

The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure. The primary clinical effectiveness endpoint is the proportion of subjects with a composite improvement of at least 1 Rutherford category and patency as evaluated by duplex ultrasound at 4 weeks after index procedure.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2020
Est. primary completion date September 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

1. Subject has signed informed consent

2. Subject is = 21 years of age

3. Subject is able and willing to comply with study requirements

4. Male, infertile female, or female practicing contraception and a negative pregnancy test within 7 days prior to the study procedure

5. Symptomatic claudication or rest pain without tissue loss, Rutherford category 2-4

6. Angiographic evidence of de novo or restenotic target lesion(s) in native vessels in the common and/or external iliac artery(ies) (multiple stenoses may exist within the target lesion)

7. Total lesion(s) length is = 110mm

8. Target lesion(s) is at least 3 cm from an existing stent or stent graft

9. At least 1 stenosis in the target vessel has = 50% stenosis

10. Target vessel diameter is between 4.6 and 14.4mm at angiographic screening for device placement

11. Adequate ipsilateral blood flow, including at least 1 patent (<50% stenotic) superficial femoral or profundal femoral artery

12. Full expansion of an appropriately sized (in the investigator's opinion) standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment

Exclusion Criteria:

1. Subject has undergone an intervention (surgical or percutaneous) in the target limb(s) <30 days from the date of the index study procedure

2. Subject has a surgical or percutaneous procedure in the target limb(s) planned within 30 days following the index study procedure

3. Previous or planned bypass surgery in the target limb(s)

4. Coronary intervention within 30 days prior to enrollment or planned within 12 months after index study procedure

5. Subject has had a stroke within 90 days prior to the index study procedure

6. Subject has had a transient ischemic attack within 30 days prior to the index study procedure

7. Uncorrectable coagulation disorder

8. Subject cannot receive heparin, dual antiplatelet treatment, or anticoagulant(s) appropriate in the opinion of the investigator

9. Condition unrelated to study anticipated to require indefinite anticoagulation

10. Evidence of blood borne infection

11. Hypersensitivity to nickel titanium alloy

12. Allergy to radiographic contrast material which cannot be adequately premedicated

13. Serum creatinine >2.5mg/dL

14. The subject is enrolled in another investigational study

15. Life expectancy is = 12 months

16. Active malignancy other than non-melanomatous skin cancer

17. Stenosis/restenosis is located within a previously placed stent or stent graft

18. Angiographic evidence of thrombus within or adjacent to the target lesion(s)

19. Aneurysmal dilation proximal or distal to the target lesion(s) that could interfere with placement of the study device

20. Abdominal aortic artery stent, if it could interfere with placement of the study device

21. Target lesion(s) are located such that the stent graft would prevent blood flow to the internal iliac artery, if patent

22. Lesions requiring atherectomy or ablation to facilitate stent graft delivery

23. Any other condition deemed exclusionary in the opinion of the investigator for documented reasons relating to the health and/or welfare of the subject

Study Design


Intervention

Device:
Placement of WRAPSODY stent graft
Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merit Medical Systems, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Safety endpoint of subjects free from specified adverse events The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure. 4 weeks after placement of WRAPSODY stent graft
Primary Effectiveness endpoint of subjects with improvement of Rutherford Category The primary clinical effectiveness endpoint is the proportion of subjects with improvement of at least 1 Rutherford category within 4 weeks of the index procedure. Composite with Outcome 3. 4 weeks after placement of WRAPSODY stent graft
Primary Effectiveness endpoint of subjects with patency The primary clinical effectiveness endpoint is the proportion of subjects with patency as evaluated by duplex ultrasound at 4 weeks after index procedure. Composite with Outcome 2. 4 weeks after placement of WRAPSODY stent graft
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1